The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Kizoo aims to cure ageing
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
C4X shows being early to the party can bring success
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
Cognito’s Alzheimer’s brainwave
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
Point’s path leads to a Spac
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
